Glycogen Synthase Kinase 3β in Cancer Biology and Treatment
Glycogen synthase kinase (GSK)3β is a multifunctional serine/threonine protein kinase with more than 100 substrates and interacting molecules. GSK3β is normally active in cells and negative regulation of GSK3β activity via phosphorylation of its serine 9 residue is required for most normal cells to...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/9/6/1388 |
| _version_ | 1827715720734048256 |
|---|---|
| author | Takahiro Domoto Masahiro Uehara Dilireba Bolidong Toshinari Minamoto |
| author_facet | Takahiro Domoto Masahiro Uehara Dilireba Bolidong Toshinari Minamoto |
| author_sort | Takahiro Domoto |
| collection | DOAJ |
| description | Glycogen synthase kinase (GSK)3β is a multifunctional serine/threonine protein kinase with more than 100 substrates and interacting molecules. GSK3β is normally active in cells and negative regulation of GSK3β activity via phosphorylation of its serine 9 residue is required for most normal cells to maintain homeostasis. Aberrant expression and activity of GSK3β contributes to the pathogenesis and progression of common recalcitrant diseases such as glucose intolerance, neurodegenerative disorders and cancer. Despite recognized roles against several proto-oncoproteins and mediators of the epithelial–mesenchymal transition, deregulated GSK3β also participates in tumor cell survival, evasion of apoptosis, proliferation and invasion, as well as sustaining cancer stemness and inducing therapy resistance. A therapeutic effect from GSK3β inhibition has been demonstrated in 25 different cancer types. Moreover, there is increasing evidence that GSK3β inhibition protects normal cells and tissues from the harmful effects associated with conventional cancer therapies. Here, we review the evidence supporting aberrant GSK3β as a hallmark property of cancer and highlight the beneficial effects of GSK3β inhibition on normal cells and tissues during cancer therapy. The biological rationale for targeting GSK3β in the treatment of cancer is also discussed at length. |
| first_indexed | 2024-03-10T19:24:52Z |
| format | Article |
| id | doaj.art-883899283ccd49418461102243467b6c |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T19:24:52Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-883899283ccd49418461102243467b6c2023-11-20T02:41:21ZengMDPI AGCells2073-44092020-06-0196138810.3390/cells9061388Glycogen Synthase Kinase 3β in Cancer Biology and TreatmentTakahiro Domoto0Masahiro Uehara1Dilireba Bolidong2Toshinari Minamoto3Division of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa 920-0934, JapanDivision of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa 920-0934, JapanDivision of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa 920-0934, JapanDivision of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa 920-0934, JapanGlycogen synthase kinase (GSK)3β is a multifunctional serine/threonine protein kinase with more than 100 substrates and interacting molecules. GSK3β is normally active in cells and negative regulation of GSK3β activity via phosphorylation of its serine 9 residue is required for most normal cells to maintain homeostasis. Aberrant expression and activity of GSK3β contributes to the pathogenesis and progression of common recalcitrant diseases such as glucose intolerance, neurodegenerative disorders and cancer. Despite recognized roles against several proto-oncoproteins and mediators of the epithelial–mesenchymal transition, deregulated GSK3β also participates in tumor cell survival, evasion of apoptosis, proliferation and invasion, as well as sustaining cancer stemness and inducing therapy resistance. A therapeutic effect from GSK3β inhibition has been demonstrated in 25 different cancer types. Moreover, there is increasing evidence that GSK3β inhibition protects normal cells and tissues from the harmful effects associated with conventional cancer therapies. Here, we review the evidence supporting aberrant GSK3β as a hallmark property of cancer and highlight the beneficial effects of GSK3β inhibition on normal cells and tissues during cancer therapy. The biological rationale for targeting GSK3β in the treatment of cancer is also discussed at length.https://www.mdpi.com/2073-4409/9/6/1388glycogen synthase kinase 3βcancerbiologytreatment |
| spellingShingle | Takahiro Domoto Masahiro Uehara Dilireba Bolidong Toshinari Minamoto Glycogen Synthase Kinase 3β in Cancer Biology and Treatment Cells glycogen synthase kinase 3β cancer biology treatment |
| title | Glycogen Synthase Kinase 3β in Cancer Biology and Treatment |
| title_full | Glycogen Synthase Kinase 3β in Cancer Biology and Treatment |
| title_fullStr | Glycogen Synthase Kinase 3β in Cancer Biology and Treatment |
| title_full_unstemmed | Glycogen Synthase Kinase 3β in Cancer Biology and Treatment |
| title_short | Glycogen Synthase Kinase 3β in Cancer Biology and Treatment |
| title_sort | glycogen synthase kinase 3β in cancer biology and treatment |
| topic | glycogen synthase kinase 3β cancer biology treatment |
| url | https://www.mdpi.com/2073-4409/9/6/1388 |
| work_keys_str_mv | AT takahirodomoto glycogensynthasekinase3bincancerbiologyandtreatment AT masahirouehara glycogensynthasekinase3bincancerbiologyandtreatment AT dilirebabolidong glycogensynthasekinase3bincancerbiologyandtreatment AT toshinariminamoto glycogensynthasekinase3bincancerbiologyandtreatment |